The controlling shareholder is injecting ~$5M in new equity, signaling continued financial support and alignment. Monitor the closing by October 29 and any subsequent use of proceeds disclosures. No activist demands or strategic changes were announced — this is a routine capital raise from the majority owner.
Price Chart
Executive Summary
Sealbond Ltd, the majority owner of Dogwood Therapeutics, filed Amendment No. 3 to its Schedule 13D, reporting a new private placement subscription agreement to purchase 4,098,360 shares at $1.22/share, expected to close by October 29, 2026. Sealbond directly holds 21,822,333 shares (63.9% of outstanding common stock as of September 30, 2026), and together with affiliate Conjoint Inc. (2,842,638 shares, 8.3%), the group controls 72.3% of the company. This is a capital infusion from the controlling shareholder, not a change in control or activist escalation.
Key Financial Metrics
Key Facts
- Sealbond Ltd entered a Subscription Agreement on October 19, 2026 to purchase 4,098,360 shares at $1.22/share in a private placement.
- Sealbond directly owns 21,822,333 shares (63.9% of 34,129,553 shares outstanding as of September 30, 2026).
- Affiliate Conjoint Inc. directly owns 2,842,638 shares (8.3%).
- Combined beneficial ownership of CK Life Sciences group (Sealbond + Conjoint) is 24,664,971 shares (72.3%).
- The closing is expected on or before October 29, 2026.
- A Registration Rights Agreement was signed to register the resale of the new shares.
- No transactions in common stock were effected by the reporting persons in the past 60 days.
Financial Impact
Sealbond is investing approximately $5.0 million ($1.22/share × 4,098,360 shares) into Dogwood via a private placement, increasing its stake from 63.9% to approximately 66.7% (assuming no other share changes).
Risk Factors
- Dilution to minority shareholders from the 4.1M new shares.
- If the private placement does not close by October 29, it may signal a funding shortfall or execution risk.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001104659-26-117841 |
| Document: 0001104659-26-117841-index.html | 0001104659-26-117841 |
| Document: 0001104659-26-117841.txt | 0001104659-26-117841 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.12 (+0.16%) |
Oct 19, 2026 7d ago | 8-K | $1.21 | awaiting T+60 | — | $1.12 (−7.29%) |
Oct 19, 2026 7d ago | Press Release | $1.21 | awaiting T+60 | — | $1.12 (−7.29%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.12 (+43.34%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.12 (−34.01%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.34%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.34%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.12 (−34.40%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.12 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers